Gökhan Öztürk

Dr. Gökhan Öztürk

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
GÖGökhan Öztürk
Gökhan Öztürk
ETEbru Taştekin
Ebru Taştekin
CTCanberk Topuz
Canberk Topuz
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
TATayyip İlker Aydın
Tayyip İlker Aydın
AKAhmet Küçükarda
Ahmet Küçükarda
Background and Objectives: The Gustave Roussy Immune (GRIm) score, reflecting systemic inflammation and nutritional status, has emerged as a simple and reproducible prognostic biomarker in various malignancies. However, its prognostic interaction with tumor microenvironmental factors remains unclear in gastric cancer. The primary aim of this study was to evaluate the prognostic value of the GRIm score in patients with resectable gastric adenocarcinoma, while the secondary aim was to determine whether integrating the GRIm score with tumor microenvironment–related pathological markers could improve prognostic stratification. Materials and Methods: This retrospective study analyzed 188 patients with resectable gastric adenocarcinoma treated at the Trakya University Faculty of Medicine between 2007 and 2018. GRIm scores were calculated from preoperative lactate dehydrogenase (LDH), albumin, and neutrophil-to-lymphocyte ratio (NLR) values. Pathologic parameters, including programmed death-ligand 1 (PD-L1) expression (combined positive score [CPS] ≥ 1 vs. <1), tumor–stroma ratio (TSR; stromal component ≥ 50% vs. <50%), and tumor-infiltrating lymphocyte (TIL) density (CD8+ ≥ 10% vs. <10%), were evaluated on surgical specimens. Survival outcomes were assessed using Kaplan–Meier and multivariate Cox analyses. Results: The study population had a mean age of 61.8 years and was predominantly male (72.3%). Patients with low GRIm scores had significantly longer disease-free survival (DFS; 24 vs. 12 months; p = 0.004) and overall survival (OS; 32 vs. 19 months; p = 0.006). In multivariate analysis, the GRIm score remained an independent predictor for both disease-free survival (p = 0.035) and overall survival (p = 0.044). Among combined models, the GRIm–TSR classification provided the most pronounced stratification (median DFS = 35 vs. 12 months; OS = 45 vs. 19 months; p = 0.014 and 0.001, respectively), retaining independent prognostic significance (hazard ratio [HR] = 1.23; p = 0.005). Integrating GRIm with PD-L1 and TIL density also improved prognostic discrimination. Conclusions: The GRIm score is a robust and cost-effective biomarker that independently predicts disease-free survival and overall survival in resectable gastric adenocarcinoma. Its combination with microenvironmental markers—PD-L1, TIL, and TSR—captures complementary biological dimensions of tumor aggressiveness, offering an integrative and clinically feasible framework for individualized risk assessment and postoperative management. Prospective multicenter validation is warranted.

2 July 2025 in Balkan Medical Journal
Verified
Journal Article
Open access
GÖGökhan Öztürk
Gökhan Öztürk
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
MHMuhammet Bekir Hacıoğlu
Muhammet Bekir Hacıoğlu
SSSerdar Solak
Serdar Solak
EÇElif Nur Çatalbaş
Elif Nur Çatalbaş

11 February 2026 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
STSalih Tunbekici
Salih Tunbekici
HBHamit Bal
Hamit Bal
OKOğuzcan Kınıkoğlu
Oğuzcan Kınıkoğlu
HAHayati Arvas
Hayati Arvas
HMHarun Muğlu
Harun Muğlu
EGERDEM GOKER
ERDEM GOKER

13 January 2026 in Acta Haematologica Oncologica Turcica
Verified
Journal Article
Open access
PDF file
GÖGökhan Öztürk
Gökhan Öztürk
NTNermin Tunçbilek
Nermin Tunçbilek
STSernaz Topaloğlu
Sernaz Topaloğlu
BKBüşra Kıyıcı
Büşra Kıyıcı
Therapeutic Response Heterogeneity in the Neoadjuvant Setting: Observations from a Case of HER2-positive, Hormone Receptor-negative Breast Cancer - Acta Haematologica Oncologica Turcica

31 October 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
ETEbru Taştekin
Ebru Taştekin
GÖGökhan Öztürk
Gökhan Öztürk
TATayyip İlker Aydın
Tayyip İlker Aydın
BEBülent Erdoğan
Bülent Erdoğan
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
Androgen receptor (AR) signaling may influence endocrine responsiveness in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negativ

26 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
HKHilmi Kodaz
Hilmi Kodaz
ÇKÇağnur Elpen Kodaz
Çağnur Elpen Kodaz
GÖGökhan Öztürk
Gökhan Öztürk
IBIsmail Beypinar
Ismail Beypinar
Background and Objectives: Early progression (PFS < 90 days) in NSCLC patients undergoing ICI treatment constitutes a significant clinical challenge. Although predictive biomarkers have been extensively investigated, specific transcriptomic and immune microenvironment characteristics contributing to early progression remain inadequately characterized. Materials and Methods: We analyzed RNA-seq data from 27 NSCLC patients receiving anti-PD-1/PD-L1 therapy (GSE135222). Patients were categorized as Early Progression (PFS < 90 days; n = 17) or Clinical Benefit (PFS ≥ 90 days; n = 10). GSEA was performed with Hallmark and C7 ImmuneSigDB gene sets. Immune cell deconvolution was performed using EPIC. An 87-gene immunosuppressive risk score was derived from TGF-β, WNT/β-catenin, and EMT pathway leading-edge genes. Results: GSEA identified 17 significantly enriched Hallmark pathways in early progressors, predominantly immunosuppressive (TGF-β, WNT/β-catenin) and oncogenic (MYC targets, E2F targets, G2M checkpoint) programs. C7 ImmuneSigDB analysis revealed 131 enriched immune signatures including CD8 T cell dysfunction, Treg activation, and M2 macrophage polarization. An 87-gene immunosuppressive risk score demonstrated a significant negative correlation with PFS (Spearman ρ = −0.516, p = 0.006) and a trend toward poorer survival outcomes (HR = 2.12, p = 0.093). Conclusions: In NSCLC patients receiving ICI, early disease progression is marked by simultaneous activation of TGF-β/WNT-mediated immunosuppressive pathways, oncogenic signaling, and CD8 T cell dysfunction. The 87-gene immunosuppressive risk score demonstrates a statistically significant negative correlation with PFS (Spearman ρ = −0.516, p = 0.006); however, given the small sample size (n = 27) and absence of external validation, these findings should be interpreted as exploratory and hypothesis-generating, warranting prospective validation in independent cohorts.